JPH0541606B2 - - Google Patents
Info
- Publication number
- JPH0541606B2 JPH0541606B2 JP62085436A JP8543687A JPH0541606B2 JP H0541606 B2 JPH0541606 B2 JP H0541606B2 JP 62085436 A JP62085436 A JP 62085436A JP 8543687 A JP8543687 A JP 8543687A JP H0541606 B2 JPH0541606 B2 JP H0541606B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- bone
- glucose
- hypocalcemia
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011575 calcium Substances 0.000 claims description 23
- 229910052791 calcium Inorganic materials 0.000 claims description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- 208000013038 Hypocalcemia Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000000705 hypocalcaemia Effects 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 150000002402 hexoses Chemical class 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 description 22
- 239000001506 calcium phosphate Substances 0.000 description 13
- 229910000389 calcium phosphate Inorganic materials 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000008213 purified water Substances 0.000 description 10
- 230000003449 preventive effect Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- -1 hexose calcium phosphate Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 208000005368 osteomalacia Diseases 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000492333 Harpa Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- YKVGWOWERSDKRZ-ZQNYHYCUSA-H P(=O)([O-])([O-])[O-].[Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] YKVGWOWERSDKRZ-ZQNYHYCUSA-H 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- TVBSSDNEJWXWFP-UHFFFAOYSA-N nitric acid perchloric acid Chemical compound O[N+]([O-])=O.OCl(=O)(=O)=O TVBSSDNEJWXWFP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62085436A JPS6422A (en) | 1987-02-12 | 1987-04-07 | Prophylactic and remedy for hypocalcemia and bone catabolism |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3051387 | 1987-02-12 | ||
| JP62-30513 | 1987-02-12 | ||
| JP62085436A JPS6422A (en) | 1987-02-12 | 1987-04-07 | Prophylactic and remedy for hypocalcemia and bone catabolism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH0122A JPH0122A (ja) | 1989-01-05 |
| JPS6422A JPS6422A (en) | 1989-01-05 |
| JPH0541606B2 true JPH0541606B2 (enrdf_load_stackoverflow) | 1993-06-24 |
Family
ID=12305891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62085436A Granted JPS6422A (en) | 1987-02-12 | 1987-04-07 | Prophylactic and remedy for hypocalcemia and bone catabolism |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6422A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4485169B2 (ja) | 2003-05-16 | 2010-06-16 | 花王株式会社 | 腸管ミネラル吸収能改善剤 |
| JP4634027B2 (ja) * | 2003-05-16 | 2011-02-16 | 花王株式会社 | ビタミンｄ様活性代替用剤 |
-
1987
- 1987-04-07 JP JP62085436A patent/JPS6422A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6422A (en) | 1989-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0329708B1 (en) | Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid | |
| US5128374A (en) | Use of calcium citrate malate for the treatment of osteoporosis and related disorders | |
| JP2010505818A (ja) | 甲殻類の胃石成分を含む組成物とその使用 | |
| AU625809B2 (en) | Novel calcium supplements | |
| US5314919A (en) | Calcium supplements | |
| CA1329774C (en) | Methods for the treatment of osteoporosis and related disorders | |
| JP2003504384A (ja) | クエン酸カリウムカルシウム組成物および製造方法 | |
| JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
| CN100534998C (zh) | 果糖-1,6-二磷酸-钙盐的制备及其应用 | |
| US4101668A (en) | Antiosteoporotic agents | |
| US6441041B1 (en) | (-)-hydroxycitric acid for the prevention of osteoporosis | |
| US6887897B2 (en) | Calcium glutarate supplement and phosphorus binder | |
| JPH0541606B2 (enrdf_load_stackoverflow) | ||
| Forbes | 422 IS HUMAN MILK THE BEST FOOD FOR LOW BIRTH WEIGHT BABIES? | |
| US20040048925A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
| Carlini et al. | Methyleugenol as a surgical anesthetic in rodents | |
| US20040220266A1 (en) | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives | |
| Slatopolsky et al. | Alternative phosphate binders in dialysis patients: calcium carbonate | |
| JPH0563452B2 (enrdf_load_stackoverflow) | ||
| AU651824B2 (en) | Pharmaceutical composition | |
| JPH0122A (ja) | 低カルシウム血症及び骨代謝異常症の予防・治療剤 | |
| RU2356546C1 (ru) | Фармацевтический состав на основе сигетина для профилактики и лечения остеопороза (варианты) | |
| Whitford et al. | Fluoride absorption: independence from plasma fluoride levels | |
| JP2616845B2 (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
| JPH02221230A (ja) | 骨粗鬆症予防剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070624 Year of fee payment: 14 |